Being tested
Glatiramer acetate: slow disability worsening in secondary progressive MS
secondary progressive MS · Glatiramer acetate
Trials are running now and no controlled trial has a readable result yet.
- Trials
- 2
- Running now
- 1
- Controlled phase 2/3 trials
- 0
- People in controlled trials
- 0
No controlled trial has reported a result yet.
Other linked trials: 2
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Trials
Other linked trials: 2
These linked trials do not set the status.
- STOP-I-SEPOngoing
Phase 3 · 2019 · Compared with cyclophosphamide anhydrous, dimethyl fumarate, fingolimod, glatiramer acetate, interferon beta-1a, interferon beta-1b, mycophenolate mofetil, natalizumab, teriflunomide
- Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis PatientsNo result found
Phase 2/3 · 2017 · Not randomised
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-10-28Trials: 1 → 2
- 2026-10-28Status changed from No clear answer to Being tested
- 2026-10-27First listed as No clear answer
Related hypotheses
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error